Literature DB >> 29715146

A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.

Takuya Owari1, Makito Miyake2, Yasushi Nakai1, Yosuke Morizawa1, Shunta Hori1, Satoshi Anai1, Nobumichi Tanaka1, Kiyohide Fujimoto1.   

Abstract

AIM: The aim of this study was to develop a risk scoring system specific to patients with bone metastasis of genitourinary cancer.
MATERIALS AND METHODS: This study included 180 patients with bone metastasis of three major types of genitourinary cancer: prostate cancer (n=111), renal cell carcinoma (n=43,), and urothelial carcinoma (n=26). Clinical factors at diagnosis of bone metastasis were evaluated to identify independent prognostic factors.
RESULTS: Multivariate analysis showed that type of primary cancer, poor performance status, the presence of visceral metastases, high Glasgow prognostic score and elevated neutrophil-to-lymphocyte ratio were independently predictive of poor prognosis. Patients were able to be classified by the prognostic risk score into four prognostic groups with low, intermediate, high, and very high risk.
CONCLUSION: This risk scoring system could be useful for predicting survival of patients with bone metastasis of genitourinary cancer and in making decisions on appropriate treatments for them. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Bone metastasis; genitourinary cancer; predicting survival; prognostic factor; scoring system

Mesh:

Year:  2018        PMID: 29715146     DOI: 10.21873/anticanres.12568

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy.

Authors:  Makito Miyake; Takuya Owari; Kiyohide Fujimoto
Journal:  Ann Transl Med       Date:  2019-07

2.  Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.

Authors:  Jacqueline T Brown; Yuan Liu; Julie M Shabto; Dylan J Martini; Deepak Ravindranathan; Emilie Elise Hitron; Greta Anne Russler; Sarah Caulfield; Lauren Beth Yantorni; Shreyas S Joshi; Haydn Kissick; Kenneth Ogan; Wayne B Harris; Bradley C Carthon; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen
Journal:  Oncologist       Date:  2021-03-18

3.  Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.

Authors:  Feng Qi; Yunqiu Xu; Yuxiao Zheng; Xiao Li; Yang Gao
Journal:  Ann Transl Med       Date:  2019-10

4.  Prognostic Scoring System Development for Malignant Spinal Cord Compression.

Authors:  Chaichana Chantharakhit; Nantapa Sujaritvanichpong
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

5.  External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy.

Authors:  Takuya Owari; Makito Miyake; Yasushi Nakai; Nobumichi Tanaka; Yoshitaka Itami; Shuya Hirao; Hitoshi Momose; Yoshinori Nakagawa; Kouta Iida; Fumisato Maesaka; Takuto Shimizu; Yusuke Iemura; Yoshihiro Matsumoto; Masaomi Kuwada; Takeshi Otani; Kenji Otsuka; Eijiro Okajima; Yukinari Hosokawa; Ryosuke Okamura; Kiyohide Fujimoto
Journal:  J Bone Oncol       Date:  2020-12-13       Impact factor: 4.072

6.  Establishment and Validation of a Machine Learning Prediction Model Based on Big Data for Predicting the Risk of Bone Metastasis in Renal Cell Carcinoma Patients.

Authors:  Chan Xu; Wencai Liu; Chengliang Yin; Wanying Li; Jingjing Liu; Wanli Sheng; Haotong Tang; Wenle Li; Qingqing Zhang
Journal:  Comput Math Methods Med       Date:  2022-10-03       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.